Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-α blocker in the treatment of rheumatic diseases

Journal of Rheumatology

Volumn 37, Issue 2, 2010, Pages 346-350

  Kim, Yun Jung ^a   Bae, Sang Cheol ^b   Sung, Yoon Kyoung ^b   Kim, Tae Hwan ^b   Jun, Jae Bum ^b   Yoo, Dae Hyun ^b   Kim, Tae Yeob ^a   Sohn, Joo Hyun ^a   Lee, Hye Soon ^a  

^a Hanyang University Guri Hospital   (South Korea)

^b Hanyang University College of Medicine   (South Korea)

Author keywords

Hepatitis B virus; Occult infection; Rheumatic diseases; Tumor necrosis factor blocker

Indexed keywords

ADALIMUMAB; AMINOTRANSFERASE; ETANERCEPT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; INFLIXIMAB; MEMBRANE ANTIGEN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FUNCTION TEST; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; RISK FACTOR; SEROLOGY; VIRUS LOAD;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DISEASE SUSCEPTIBILITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES;

EID: 76649143366     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090436     Document Type: Article

References (27)

1. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
2. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
3. St. Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
4. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004;350:1118-29.
5. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003;30:1624-5.
6. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006;12:974-6.
7. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003;62:686-7.
8. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology 2006;45:1294-7.
9. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008;35:421-4.
10. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008;38:208-17.
11. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006;65:983-9.
12. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006;21:1366-71.
13. Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airo P. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009;36:1188-94.
14. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36.
15. Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF. Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum 2005;52:2968-74.
16. Yun H, Kim D, Kim S, Kang S, Jeong S, Cheon Y, et al. High prevalence of HBV and HCV infection among intravenous drug users in Korea. J Med Virol 2008;80:1570-5.
17. Lee DH, Kim JH, Nam JJ, Kim HR, Shin HR. Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J Korean Med Sci 2002;17:457-62.
18. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91.
19. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
20. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-20.
21. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39.
22. Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 2003;38:4-13.
23. Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000;31:488-95.
24. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003;37:1172-9.
25. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005;11:189-91.
26. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007;13:508-9.
27. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68-9.